Online inquiry

IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10901MR)

This product GTTS-WQ10901MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL1A gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC), Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000575.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3552
UniProt ID P01583
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ10901MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13080MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ3355MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ6168MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ3497MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ9964MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ5207MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CAT-8015
GTTS-WQ13549MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRX-302
GTTS-WQ9161MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMGN-529
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW